SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

BPGbio Presents Phase 2 Glioblastoma Data With 19.9-Month Median Survival

BPGbio reported median overall survival of 19.9 months among patients with MGMT-unmethylated glioblastoma. The source headline says the data were presented at ESMO Congress 2026.

Related stories